Pentazocin

PENTAZOCINE Struktur
359-83-1
CAS-Nr.
359-83-1
Bezeichnung:
Pentazocin
Englisch Name:
PENTAZOCINE
Synonyma:
Lexir;C07421;II-C-2;Talwan;Talwin;Fortral;KF-1820;Liticon;nih7958;sosegon
CBNumber:
CB1121418
Summenformel:
C19H27NO
Molgewicht:
285.43
MOL-Datei:
359-83-1.mol

Pentazocin Eigenschaften

Schmelzpunkt:
145.4-147.20C
Siedepunkt:
427.85°C (rough estimate)
Dichte
1.0104 (rough estimate)
Brechungsindex
1.5180 (estimate)
Flammpunkt:
9℃
storage temp. 
Controlled Substance, -20°C Freezer
Löslichkeit
DMSO: >10mg/mL
pka
pKa 8.68±0.05;11.23± 0.05(H2O,t =20,I=0.1) (Uncertain)
Aggregatzustand
solid
Farbe
white
CAS Datenbank
359-83-1
EPA chemische Informationen
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2R,6R,11R)-rel- (359-83-1)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xn,T,F
R-Sätze: 22-39/23/24/25-23/24/25-11
S-Sätze: 7-16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  3
RTECS-Nr. PB8750000
HS Code  2933330000
Giftige Stoffe Daten 359-83-1(Hazardous Substances Data)
Toxizität LD50 s.c. in male rats: 175±36 mg/kg (Goldenthal)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
Sicherheit
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P301+P312 BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Pentazocin Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R22:Gesundheitsschädlich beim Verschlucken.

Chemische Eigenschaften

Crystalline Solid

Verwenden

(?)-Pentazocine is a benzomorphan-type opiate with analgesic properties. It binds to opioid receptors (Ki values = 7.2, 31, and 5.7 nM for κ-, δ-, μ-opioid receptors, respectively) and to the type 1 σ-receptor (Kd = 12 nM). (?)-Pentazocine is abused with methylphenidate and other drugs. It is regulated as a Schedule IV compound in the United States. This product is intended for forensic and research applications.

Weltgesundheitsorganisation (WHO)

Pentazocine, which has both agonist and weak opioid antagonist activity, was introduced in 1967 for the treatment of moderate and severe pain. The risk of drug dependence is lower with pentazocine than with morphine-like drugs and pentazocine has been controlled under Section III of the 1971 Convention on Psychotropic Substances since 1984. The risk of dependence is now widely acknowledged to exist in vulnerable individuals and at least one country has applied controls analogous to those of Schedule I of the 1961 Single Convention on Narcotic Drugs. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

Allgemeine Beschreibung

The benzomorphans are prepared synthetically and thus resultin several stereoisomers. The active benzomorphans arethose that have the equivalent bridgehead carbons in thesame absolute configuration of morphine (carbons 9, 13,and 14 of morphine). The only benzomorphan in clinical useis pentazocine, which is prepared as the 2(R), 6(R), 11(R)enantiomer (Chemical Abstracts numbering). Pentazocineis a mixed agonist/antagonist displaying differing intrinsicactivity at the opioid receptor subtypes. At the κ-receptor,pentazocine is a partial agonist and a weak antagonist.
According to the manufacturer, a 50-mg dose of pentazocinehas about the same analgesic potency as 60 mg of codeineand about 1/50th the antagonistic activity of nalorphine.74Pentazocine is also an agonist at the κ-receptor, and thismay be responsible for the higher percentage of patients thatexperience dysphoria with pentazocine versus morphine.75Some evidence also exists that women respond better to κ-agonists than men. Pentazocine is available in a 50-mgtablet along with a low dose of the antagonist naloxone 0.5mg (Talwin NX). Naloxone 0.5 mg orally is expected tohave no pharmacological effect but is included to dissuadeIV drug abusers from dissolving and injecting Talwin NX.

Sicherheitsprofil

Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dernlititis. Can cause drug dependency and other central nervous system effects, An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLIT COMPOUNDS.

Pentazocin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

359-83-1(Pentazocin)Verwandte Suche:


  • C07421
  • Pentazocine CIV (500 mg)
  • 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-diMethyl-3-(3-Methyl-2-buten-1-yl)-,(2R,6R,11R)-rel-
  • Pentazocine solution
  • PENTAZOCINE
  • (2alpha,6alpha,11r*)-2-butenyl)
  • (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
  • 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benza
  • 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan
  • 2-(3,3-dimethylallyl)-2’,2’-hydroxy-5,9-dimethyl-6,7-benzomorphan
  • 2-(3,3-Dimethylallyl)cyclazocine
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R)-
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-
  • 2’-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • 2-butenyl)-
  • 2-dimethylallyl-5,9-dimethyl-2’-hydroxybenzomorphan
  • 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan
  • 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • 3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-ben
  • 3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benza
  • 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
  • 6r*,11r*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-(2r
  • dl-2’-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • dl-2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
  • Fortalgesic
  • cis-(-Pentazocine
  • Win 2022
  • Pentazocinum
  • 1,2,3,4,5,6-Hexahydro-3-(3-methyl-2-butenyl)-6,11-dimethyl-8-hydroxy-2,6-methano-3-benzazocine
  • 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2a,6a,11R*)- (8CI)
  • 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel- (9CI)
  • 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocine
  • dl-Pentazocine
  • Lexir
  • Peltazon
  • Pentazocine (base and/or unspecified salts)
  • Fortalin
  • Fortral
  • II-C-2
  • KF-1820
  • Liticon
  • L-pentazocine
  • methano-3-benzazocin-8-ol
  • NIH 7958
  • nih7958
  • NSC-107430
  • Pentagin
  • Pentazocaine
  • Pentazocin
  • sosegon
  • Soseton
  • Sosigon
  • Talwan
  • Talwin
  • Win 20228
  • zocin-8-ol
Copyright 2019 © ChemicalBook. All rights reserved